INMB Q3 2025 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$35M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$28,000

Operating Income

-$7M

Net Income

-$6M

EPS (Diluted)

$-0.24

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$33M

Total Liabilities

$8M

Stockholders' Equity

$25M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$28,000	$0	—
Operating Income	-$7M	-$12M	+39.5%
Net Income	-$6M	-$12M	+46.5%